DEFA14A: Tharimmune Clarifies Director Independence for Special Meeting

Tharimmune, Inc. issued a supplement to its proxy statement clarifying the independent status of two director nominees for its upcoming Special Meeting of Stockholders.

Summary

• This document is a supplement to the definitive proxy statement on Schedule 14A, originally dated January 16, 2026.
• The purpose of the supplement is to clarify information regarding the independence status of proposed nominees to the Company's Board of Directors.
• The Board nominated Ms. Jill E. Sommers and Mr. William Wiley to serve as directors, pending stockholder approval.
• The Board conducted a review and determined that both William Wiley and Jill E. Sommers are independent in accordance with applicable rules of the Nasdaq Stock Market LLC.
• This supplement does not alter the proposals to be voted on at the Special Meeting, including Proposal 1, the Election of Directors.
• Existing proxy cards or voting instruction forms remain valid, and stockholders who have already submitted their vote do not need to take further action.

Sentiment

Score: 6

Explanation: The filing is a neutral, procedural update clarifying director independence, which is a positive for corporate governance but does not contain information that would significantly alter the company's financial outlook or operational performance.

Positives

• The Board nominees, William Wiley and Jill E. Sommers, have been confirmed as independent according to Nasdaq rules, which is a positive for corporate governance and investor confidence.
• The company is providing clear and transparent information to stockholders regarding director qualifications, demonstrating adherence to regulatory standards.

Future Outlook

NA

Management Comments

• This Supplement has been prepared to clarify to stockholders certain information regarding independence status of a proposed nominee to the Board of Directors.
• The Company urges stockholders to vote their shares prior to the Special Meeting by using one of the methods described in the Proxy Statement.

Industry Context

This announcement represents a standard corporate governance update, ensuring compliance with listing rules regarding director independence. Such clarifications are routine for publicly traded companies to maintain transparency and adhere to regulatory requirements for board composition.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Provides clarity on the independence status of director nominees, enabling more informed voting decisions at the upcoming Special Meeting.

Next Steps

• Stockholders are urged to vote their shares prior to the Special Meeting.
• The 2026 Special Meeting of Stockholders will be held on January 30, 2026, to vote on proposals including the Election of Directors.

Key Dates

Recommendation

This filing is a routine corporate governance update clarifying director independence. It does not contain any new financial or operational information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as it maintains the current stance while acknowledging the company's adherence to governance standards.

Keywords

Tharimmune, Proxy Statement, Director Independence, Corporate Governance, Special Meeting, Nasdaq Rules, Board of Directors, SEC Filing